Literature DB >> 30149394

Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.

Masaaki Motoori1,2, Kazumasa Fujitani1, Keijiro Sugimura2, Hiroshi Miyata2, Rie Nakatsuka1, Yujiro Nishizawa1, Hisateru Komatsu1, Susumu Miyazaki1, Takamichi Komori1, Masaki Kashiwazaki1, Kazuhiro Iwase1, Masahiko Yano2.   

Abstract

OBJECTIVE: Neoadjuvant therapy followed by surgery has been the standard treatment for advanced esophageal cancer. Severe toxicities may influence body composition, including skeletal muscle mass, and increase postoperative complications. The purpose of this study was to evaluate the influence of sarcopenia, changes in body composition, and adverse events during neoadjuvant chemotherapy (NACT) on postoperative complications in esophageal cancer patients.
METHODS: A total of 83 patients with esophageal cancer undergoing NACT followed by esophagectomy were included. Body composition was assessed before chemotherapy and before esophagectomy. The relationships between postoperative infectious complications and sarcopenia, changes in body composition, and adverse events during NACT were investigated.
RESULTS: Univariate analysis revealed that skeletal muscle loss during NACT, but not preoperative sarcopenia, was significantly higher in the complication (+) group. Febrile neutropenia tended to occur frequently in the complication (+) group. Multivariate analysis demonstrated that skeletal muscle loss was the only factor significantly associated with infectious complications (p = 0.029). Among adverse events, febrile neutropenia was significantly associated with a decrease in skeletal muscle mass.
CONCLUSION: Loss of skeletal muscle mass during NACT was a significant risk factor for postoperative infectious complications in patients with esophageal cancer. Prevention of severe adverse events may reduce postoperative infectious complications.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Esophageal cancer; Neoadjuvant chemotherapy; Postoperative complications; Sarcopenia; Skeletal muscle loss

Mesh:

Year:  2018        PMID: 30149394     DOI: 10.1159/000490616

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  6 in total

1.  Sarcopenia defined by muscle quality rather than quantity predicts complications following laparoscopic right hemicolectomy.

Authors:  James Tankel; Shlomo Yellinek; Elena Vainberg; Yotam David; Dmitry Greenman; James Kinross; Petachia Reissman
Journal:  Int J Colorectal Dis       Date:  2019-11-27       Impact factor: 2.571

Review 2.  Perioperative body composition changes in the multimodal treatment of gastrointestinal cancer.

Authors:  Toru Aoyama
Journal:  Surg Today       Date:  2019-04-26       Impact factor: 2.549

3.  Disease-specific Nutritional Physical Therapy: A Position Paper by the Japanese Association of Rehabilitation Nutrition (Secondary Publication).

Authors:  Tatsuro Inoue; Izumi Takeuchi; Yuki Iida; Kohei Takahashi; Fumihiko Nagano; Shinjiro Miyazaki; Kengo Shirado; Yoshihiro Yoshimura; Ryo Momosaki; Keisuke Maeda; Hidetaka Wakabayashi
Journal:  JMA J       Date:  2022-03-25

4.  Skeletal Muscle Change During Neoadjuvant Therapy and Its Impact on Prognosis in Patients With Gastrointestinal Cancers: A Systematic Review and Meta-Analysis.

Authors:  Xin-Yi Xu; Xiao-Man Jiang; Qin Xu; Hao Xu; Jin-Hua Luo; Cui Yao; Ling-Yu Ding; Shu-Qin Zhu
Journal:  Front Oncol       Date:  2022-05-27       Impact factor: 5.738

Review 5.  Management of elderly patients with esophageal squamous cell cancer.

Authors:  Yasuo Hamamoto; Kentaro Murakami; Ken Kato; Yuko Kitagawa
Journal:  Jpn J Clin Oncol       Date:  2022-08-05       Impact factor: 2.925

6.  The Impact of Preoperative Sarcopenia on Survival Prognosis in Patients Receiving Neoadjuvant Therapy for Esophageal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Sheng-Bo Jin; Zi-Bin Tian; Xue-Li Ding; Ying-Jie Guo; Tao Mao; Ya-Nan Yu; Kai-Xuan Wang; Xue Jing
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.